Table of Contents
<< Previous Issue | Mar 2025 (Vol: 2025, Issue: 3) |
- Section: Licensing
-
Biogen Gains Rights to Stoke Therapeutics’ Zorevunersen for the Treatment of Dravet Syndrome
-
AbbVie Enters Obesity Space Through US$2.2 B Licensing Pact with Gubra
-
Roche Pays Zealand Pharma US$1.65 B Upfront for Obesity Drug Petrelintide
- Section: Opinion & Analysis
-
IQVIA Pharma Deals Review of 2024
- Section: Research & Development
-
Eli Lilly Signs US$1.2 B Collaboration with Magnet Biomedicine for Molecular Glue Therapeutics
-
Takeda Signs US$816 M Collaboration with BridGene Biosciences for Small Molecule Drugs